Smyth D D, Umemura S, Pettinger W A
J Pharmacol Exp Ther. 1984 Aug;230(2):387-92.
The dose-dependent selectivity of an irreversible binding antagonist, phenoxybenzamine (POB), for renal alpha-1 adrenoceptors, was biochemically and physiologically characterized. Receptors were quantified with the radioligands [3H]prazosin and [3H]rauwolscine for alpha-1 and alpha-2 adrenoceptors, respectively. Alpha-1 adrenoceptor function was quantified by the shift of the norepinephrine and phenylephrine pressor response in vivo and the vasoconstrictor response in the isolated perfused kidney preparation. A renal alpha-2 adrenoceptor response was demonstrated by showing that epinephrine could reverse the effect of vasopressin on water and sodium in the presence of beta blockade and alpha-1 destruction by POB. Doses of POB from 0.1 to 10.0 mg/kg progressively reduced [3H]prazosin binding to renal alpha-1 adrenoceptors until there was no specific binding at the 10.0-mg/kg dose. At this dose more than 60% of [3H]rauwolscine binding to renal alpha-2 adrenoceptors was still present. POB 1.0 mg/kg/hr decreased specific binding to renal alpha-1 adrenoceptors by approximately 40% (P less than .05) but reduced the alpha-1 adrenoceptor-induced vasoconstriction in the nonrecirculating isolated perfused kidney to 10 to 20% of the control. This was the maximal dose of POB studied which did not affect the alpha-2 adrenoceptor-induced antagonism of vasopressin. Higher doses of POB (3.0 mg/kg/hr) demonstrated some alpha-2 adrenoceptor binding as indicated by an attenuation of the antagonism by alpha-2 adrenoceptors. Thus, POB displays selectivity for renal alpha-1 over alpha-2 adrenoceptors. Our data indicate that a dose of 1.0 mg/kg/hr of POB will leave alpha-2 adrenoceptors intact while functionally incapacitating alpha-1 adrenoceptors to 10 to 20% of the control value.
对不可逆结合拮抗剂苯氧苄胺(POB)作用于肾α-1肾上腺素能受体的剂量依赖性选择性进行了生化和生理学特征研究。分别用放射性配体[3H]哌唑嗪和[3H]育亨宾对α-1和α-2肾上腺素能受体进行定量。α-1肾上腺素能受体功能通过体内去甲肾上腺素和去氧肾上腺素升压反应的变化以及离体灌注肾脏制剂中的血管收缩反应来定量。通过证明在β受体阻断和POB破坏α-1受体的情况下肾上腺素可逆转血管加压素对水和钠的作用,证实了肾α-2肾上腺素能受体反应。0.1至10.0mg/kg剂量的POB逐渐减少[3H]哌唑嗪与肾α-1肾上腺素能受体的结合,直至10.0mg/kg剂量时无特异性结合。在此剂量下,仍有超过60%的[3H]育亨宾与肾α-2肾上腺素能受体结合。1.0mg/kg/hr的POB使肾α-1肾上腺素能受体的特异性结合减少约40%(P<0.05),但将非循环离体灌注肾脏中α-1肾上腺素能受体诱导的血管收缩降低至对照的10%至20%。这是所研究的POB最大剂量,其不影响α-2肾上腺素能受体诱导的血管加压素拮抗作用。更高剂量的POB(3.0mg/kg/hr)显示出一些α-2肾上腺素能受体结合,表现为α-2肾上腺素能受体拮抗作用减弱。因此,POB对肾α-1肾上腺素能受体的选择性高于α-2肾上腺素能受体。我们的数据表明,1.0mg/kg/hr剂量的POB可使α-2肾上腺素能受体保持完整,而使α-1肾上腺素能受体功能丧失至对照值的10%至20%。